Literature DB >> 1398995

Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.

R G Bredius1, P C Driedijk, M F Schouten, R S Weening, T A Out.   

Abstract

To obtain information on effector functions of human immunoglobulin G2 (IgG2), we have measured the complement-activating properties of polyclonal IgG subclass antibodies against bacterial antigens. IgG1 and IgG2 were purified from serum samples from five healthy individuals, and complement activation was measured with different bacterial antigens. We used Staphylococcus aureus Wood 46 (STAW), which is a common antigen, Haemophilus influenzae type b (Hib), which is a common pathogenic microorganism in children, and formaldehyde-inactivated tetanus toxin (TT). Bacteria were incubated with antibodies and then incubated with sera from agammaglobulinemic patients as a complement source, and C3c deposition was measured by enzyme-linked immunosorbent assay. We found that anti-STAW IgG2 activated complement to a level similar to that of anti-STAW IgG1. Anti-Hib IgG1 complement activation was as much as seven times higher than that of anti-Hib IgG2 in four individuals. In one individual, anti-Hib IgG2 was more effective in complement activation than anti-Hib IgG1. Anti-TT antibodies showed patterns similar to those of anti-Hib. Our results indicate that IgG2 antibodies may contribute significantly to antibacterial defense. Also, individual differences in antibody effector functions should be taken into account when evaluating the immune status of patients and during early phase 1 studies of new vaccines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1398995      PMCID: PMC258239          DOI: 10.1128/iai.60.11.4838-4847.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE.

Authors:  H N EISEN; G W SISKIND
Journal:  Biochemistry       Date:  1964-07       Impact factor: 3.162

2.  Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement.

Authors:  F Hugo; S Krämer; S Bhakdi
Journal:  J Immunol Methods       Date:  1987-05-20       Impact factor: 2.303

3.  Antibody affinity and valence in viral neutralization.

Authors:  S E Blank; G A Leslie; L W Clem
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

4.  Selective gamma-g globulin deficiencies in patients with recurrent pyogenic infections.

Authors:  P H Schur; H Borel; E W Gelfand; C A Alper; F S Rosen
Journal:  N Engl J Med       Date:  1970-09-17       Impact factor: 91.245

5.  The relationship between antibody affinity and the efficiency of complement fixation.

Authors:  A S Fauci; M M Frank; J S Johnson
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

6.  Serum opsonic activity after immunization of adults with Haemophilus influenzae type b-diphtheria toxoid conjugate vaccine.

Authors:  K L Cates; K H Marsh; D M Granoff
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

7.  Immunospecificity and quantitation of an enzyme-linked immunosorbent assay for group B streptococcal antibody.

Authors:  B F Anthony; N F Concepcion; S A McGeary; J I Ward; D C Heiner; P Shapshak; R A Insel
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

8.  Clinical applications of immunofixation: detection and quantitation of complement activation.

Authors:  J T Whicher; J Higginson; P G Riches; S Radford
Journal:  J Clin Pathol       Date:  1980-08       Impact factor: 3.411

9.  Immunoglobulin G (IgG) subclasses and human disease.

Authors:  V A Oxelius
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

10.  pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose.

Authors:  R C Duhamel; P H Schur; K Brendel; E Meezan
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

View more
  12 in total

1.  Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF.

Authors:  A Soininen; I Seppälä; T Wuorimaa; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

2.  Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes.

Authors:  R G Bredius; C A Fijen; M De Haas; E J Kuijper; R S Weening; J G Van de Winkel; T A Out
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

3.  The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals.

Authors:  C A Fijen; R G Bredius; E J Kuijper; T A Out; M De Haas; A P De Wit; M R Daha; J G De Winkel
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

4.  Complement-mediated serum sensitivity among spirochetes that cause Lyme disease.

Authors:  A P van Dam; A Oei; R Jaspars; C Fijen; B Wilske; L Spanjaard; J Dankert
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

5.  Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18C.

Authors:  Daniel J Sikkema; Nancy A Ziembiec; Thomas R Jones; Stephen W Hildreth; Dace V Madore; Sally A Quataert
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

6.  Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.

Authors:  Casey T Nishiya; Gayle M Boxx; Kerry Robison; Carol Itatani; Thomas R Kozel; Mason X Zhang
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

7.  Solution insights into the structure of the Efb/C3 complement inhibitory complex as revealed by lysine acetylation and mass spectrometry.

Authors:  Hui Chen; Michael C Schuster; Georgia Sfyroera; Brian V Geisbrecht; John D Lambris
Journal:  J Am Soc Mass Spectrom       Date:  2008-01       Impact factor: 3.109

8.  Immunoglobulin G2 antibodies promote neutrophil killing of Actinobacillus actinomycetemcomitans.

Authors:  M E Wilson; P M Bronson; R G Hamilton
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

9.  Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.

Authors:  Richarda M de Voer; Liesbeth Mollema; Rutger M Schepp; Sabine C de Greeff; Pieter G M van Gageldonk; Hester E de Melker; Elisabeth A M Sanders; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

10.  Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.

Authors:  Daniel Holme; Helen Findlow; Samba O Sow; Olubukola T Idoko; Marie-Pierre Preziosi; George Carlone; Brian D Plikaytis; Ray Borrow
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.